172 related articles for article (PubMed ID: 23899530)
1. Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial.
Reni M; Cereda S; Milella M; Novarino A; Passardi A; Mambrini A; Di Lucca G; Aprile G; Belli C; Danova M; Bergamo F; Franceschi E; Fugazza C; Ceraulo D; Villa E
Eur J Cancer; 2013 Nov; 49(17):3609-15. PubMed ID: 23899530
[TBL] [Abstract][Full Text] [Related]
2. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
Grivas PD; Daignault S; Tagawa ST; Nanus DM; Stadler WM; Dreicer R; Kohli M; Petrylak DP; Vaughn DJ; Bylow KA; Wong SG; Sottnik JL; Keller ET; Al-Hawary M; Smith DC; Hussain M
Cancer; 2014 Mar; 120(5):692-701. PubMed ID: 24249435
[TBL] [Abstract][Full Text] [Related]
3. A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).
O'Reilly EM; Niedzwiecki D; Hall M; Hollis D; Bekaii-Saab T; Pluard T; Douglas K; Abou-Alfa GK; Kindler HL; Schilsky RL; Goldberg RM;
Oncologist; 2010; 15(12):1310-9. PubMed ID: 21148613
[TBL] [Abstract][Full Text] [Related]
4. A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
Bergmann L; Maute L; Heil G; Rüssel J; Weidmann E; Köberle D; Fuxius S; Weigang-Köhler K; Aulitzky WE; Wörmann B; Hartung G; Moritz B; Edler L; Burkholder I; Scheulen ME; Richly H
Eur J Cancer; 2015 Jan; 51(1):27-36. PubMed ID: 25459392
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer.
Schneider BJ; Gadgeel SM; Ramnath N; Wozniak AJ; Dy GK; Daignault S; Kalemkerian GP
J Thorac Oncol; 2011 Jun; 6(6):1117-20. PubMed ID: 21512407
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study.
Yi JH; Thongprasert S; Lee J; Doval DC; Park SH; Park JO; Park YS; Kang WK; Lim HY
Eur J Cancer; 2012 Jan; 48(2):196-201. PubMed ID: 22176869
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P
N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237
[TBL] [Abstract][Full Text] [Related]
8. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial.
Neychev V; Steinberg SM; Cottle-Delisle C; Merkel R; Nilubol N; Yao J; Meltzer P; Pacak K; Marx S; Kebebew E
BMJ Open; 2015 May; 5(5):e008248. PubMed ID: 25991462
[TBL] [Abstract][Full Text] [Related]
9. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
Tsimafeyeu I; Zart JS; Chung B
BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.
Cheng AL; Kang YK; Lin DY; Park JW; Kudo M; Qin S; Chung HC; Song X; Xu J; Poggi G; Omata M; Pitman Lowenthal S; Lanzalone S; Yang L; Lechuga MJ; Raymond E
J Clin Oncol; 2013 Nov; 31(32):4067-75. PubMed ID: 24081937
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.
Spigel DR; Greco FA; Rubin MS; Shipley D; Thompson DS; Lubiner ET; Eakle JF; Quinn R; Burris HA; Hainsworth JD
Lung Cancer; 2012 Aug; 77(2):359-64. PubMed ID: 22560921
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia.
Castonguay V; Lheureux S; Welch S; Mackay HJ; Hirte H; Fleming G; Morgan R; Wang L; Blattler C; Ivy PS; Oza AM
Gynecol Oncol; 2014 Aug; 134(2):274-80. PubMed ID: 24882554
[TBL] [Abstract][Full Text] [Related]
13. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.
Négrier S; Gravis G; Pérol D; Chevreau C; Delva R; Bay JO; Blanc E; Ferlay C; Geoffrois L; Rolland F; Legouffe E; Sevin E; Laguerre B; Escudier B
Lancet Oncol; 2011 Jul; 12(7):673-80. PubMed ID: 21664867
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib in patients with metastatic renal cell carcinoma.
Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
[TBL] [Abstract][Full Text] [Related]
15. Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial.
Carrato A; Swieboda-Sadlej A; Staszewska-Skurczynska M; Lim R; Roman L; Shparyk Y; Bondarenko I; Jonker DJ; Sun Y; De la Cruz JA; Williams JA; Korytowsky B; Christensen JG; Lin X; Tursi JM; Lechuga MJ; Van Cutsem E
J Clin Oncol; 2013 Apr; 31(10):1341-7. PubMed ID: 23358972
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy.
Sonpavde G; Hutson TE; Berry WR; Boehm KA; Asmar L
Clin Genitourin Cancer; 2008 Sep; 6(2):134-7. PubMed ID: 18824440
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor.
Ito T; Okusaka T; Nishida T; Yamao K; Igarashi H; Morizane C; Kondo S; Mizuno N; Hara K; Sawaki A; Hashigaki S; Kimura N; Murakami M; Ohki E; Chao RC; Imamura M
Invest New Drugs; 2013 Oct; 31(5):1265-74. PubMed ID: 23269537
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer.
Gervais R; Hainsworth JD; Blais N; Besse B; Laskin J; Hamm JT; Lipton A; Albain KS; Masters GA; Natale RB; Selaru P; Kim ST; Chao RC; Page RD
Lung Cancer; 2011 Dec; 74(3):474-80. PubMed ID: 21680048
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib and pancreatic neuroendocrine tumours. More assessment needed.
Prescrire Int; 2012 May; 21(127):123-5. PubMed ID: 22827001
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency.
Kim KH; Kim HY; Kim HR; Sun JM; Lim HY; Lee HJ; Lee S; Bae WK; Rha SY; ;
Eur J Cancer; 2014 Mar; 50(4):746-52. PubMed ID: 24332573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
